Retatrutide Phase 3 Results: What Patients Should Know Retatrutide gained more attention after the Phase 3 obesity trial results
Solid engineering prevents lag, sensible promos reward participation, and clear rules reduce confusion
"Loose skin is one of the more common negative effects, usually involving the face, abdomen, thighs and arms," she says
SGLT2i have shown robust effects in reducing heart failure hospitalization and slowing the progression of chronic kidney disease, while GLP-1 RAs have demonstrated superior efficacy in reducing atherothrombotic events, particularly non-fatal stroke
The magnitude differs: A 2025 NYU Langone study found surgical patients lost 58 pounds after two years versus 12 pounds for GLP-1 prescription patients
Larger peptides with post-translational modifications (like the fatty diacid moiety on retatrutide) are more susceptible to degradation than simpler sequences